Login to Your Account



Clinic Roundup


Wednesday, January 4, 2012

• Agile Therapeutics Inc., of Princeton, N.J., completed the final Phase III trial of AG200-15 and is on track to submit the new drug application (NDA) for the combination hormonal contraceptive patch to the FDA during the first quarter. The patch, in two Phase III trials enrolling more than 2,000 women, demonstrated its ability to deliver a low dose of ethinyl estradiol and a dose of levonorgestrel consistent with the efficacy and safety profiles of low-dose oral contraceptives.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription